Loading clinical trials...
Loading clinical trials...
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Conditions
Interventions
Placebo
250 mg CK-2017357
+1 more
Locations
15
United States
Phoenix Neurological Associates, Ltd.
Phoenix, Arizona, United States
University Neurology Associates
Fresno, California, United States
California Pacific Medical Center
San Francisco, California, United States
Mayo Clinic Florida
Jacksonville, Florida, United States
University of Kentucky
Lexington, Kentucky, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Start Date
March 1, 2010
Primary Completion Date
November 1, 2010
Completion Date
November 1, 2010
Last Updated
May 10, 2019
NCT07322003
NCT05104710
NCT03233646
NCT04715399
NCT07357428
NCT05370079
Lead Sponsor
Cytokinetics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions